The ELP2 antibody is a research tool designed to target the ELP2 (Elongator Complex Protein 2) subunit, a critical component of the Elongator complex. This highly conserved multi-subunit complex plays diverse roles in transcriptional elongation, histone acetylation, and post-translational modifications, influencing processes like cell migration, neurodevelopment, and stress response. ELP2. encoded by the *ELP2* gene, contains WD40 repeats essential for protein-protein interactions and complex assembly. Dysregulation of ELP2 has been linked to diseases, including neurodevelopmental disorders (e.g., familial cortical myoclonus epilepsy) and cancers, where it may promote tumor progression via pathways like Wnt/β-catenin. Studies also associate ELP2 with autoimmune conditions, such as rheumatoid arthritis, where it modulates inflammatory signaling.
ELP2 antibodies are widely used in Western blotting, immunofluorescence, and immunohistochemistry to detect ELP2 expression, localization, and interactions in cellular and tissue contexts. They help elucidate its role in disease mechanisms and therapeutic targeting. For instance, research using ELP2-knockout models highlights its involvement in cytokine signaling and immune cell activation. Commercial ELP2 antibodies are typically validated for specificity across human, mouse, and rat samples. Ongoing research aims to clarify ELP2's regulatory mechanisms and its potential as a biomarker or drug target in precision medicine.